Welcome to our dedicated page for TEVA PHARMACEUTICAL INDUSTRIES SEC filings (Ticker: TEVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on TEVA PHARMACEUTICAL INDUSTRIES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into TEVA PHARMACEUTICAL INDUSTRIES's regulatory disclosures and financial reporting.
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) received a notice under Rule 144 that Brian Savage, its Chief Legal Officer, may sell up to 7,028 ordinary shares through Citigroup Global Markets on or after September 18, 2026 on the NYSE. The shares include amounts from rollover awards and a cashless option exercise.
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) is the issuer of ordinary shares for which Bridger Management, LLC, on behalf of Swiftcurrent Master Fund, Ltd., has filed a notice of proposed sale under Rule 144. The notice covers 367,600 ordinary shares of TEVA to be sold through Apex Clearing Corporation on the NYSE.
The filing states an aggregate market value for the securities to be sold of $14,406,244.00 and an approximate 1,166,292,643 TEVA ordinary shares outstanding. The shares proposed to be sold were originally acquired through open market purchases on May 9, 2018. Roberto Mignone of Bridger is identified as a member of TEVA’s board of directors.
Teva Pharmaceutical Industries Ltd. (TEVA) announced multiple new senior note issuances totaling €1.5 billion and $3.2 billion through its subsidiaries Teva Finance II, III and IV on September 16, 2026. The euro tranches are €1,000,000,000 of 4.250% Senior Notes due 2033 and €500,000,000 of 4.625% Senior Notes due 2036, and the U.S. dollar tranches are $1,200,000,000 of 5.250% Senior Notes due 2032, $1,000,000,000 of 5.500% Senior Notes due 2034 and $1,000,000,000 of 5.750% Senior Notes due 2037.
Teva intends to use net proceeds primarily to fund conditional redemptions of several higher‑coupon existing notes, including 6.750% Senior Notes due 2028 and multiple sustainability‑linked notes, and for general corporate purposes. The new notes are senior unsecured obligations, fully and unconditionally guaranteed on a senior unsecured basis by Teva, with standard covenants, change‑of‑control repurchase rights at 101% of principal, and make‑whole and par call redemption provisions by series.
Teva Pharmaceutical Industries Ltd. (TEVA) reports that on September 14, 2026 its ordinary shares began trading on the New York Stock Exchange under the ticker “TEVA,” replacing its American depositary shares (ADSs). On the same date, Teva’s ADS program terminated, with each ADS exchanged for one ordinary share.
The company’s ordinary shares continue to trade on the Tel Aviv Stock Exchange under the symbol “TEVA.” Additional details are available via the investor relations section of Teva’s website.
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) is having its American Depositary Shares, each representing one ordinary share, removed from listing and registration on the New York Stock Exchange LLC under Section 12(b) of the Securities Exchange Act of 1934. The New York Stock Exchange filed a Form 25, certifying it has complied with its own rules to strike this class of securities from listing under 17 CFR 240.12d2-2(b). The company is stated to have complied with the Exchange’s rules and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of this class of securities from listing and registration.
Teva Pharmaceutical Industries Limited (TEVA), through its Dutch finance subsidiaries, is issuing an aggregate of approximately $4.9 billion (equivalent) in new senior notes across five tranches: €1.0 billion 4.250% notes due 2033, €500 million 4.625% notes due 2036, $1.0 billion 5.500% notes due 2034, $1.0 billion 5.750% notes due 2037 and $1.2 billion 5.250% notes due 2032. All notes are senior unsecured obligations of the respective finance subsidiaries and are unconditionally guaranteed on a senior unsecured basis by Teva.
The Euro tranches pay interest annually, while the USD tranches pay semi-annually, with maturities between 2032 and 2037. After underwriting discounts, per-tranche proceeds range from about €489 million to $1.18 billion, and Teva expects aggregate gross proceeds of about $4.9 billion (equivalent). Net proceeds, together with cash on hand, are expected to be used primarily to redeem or partially redeem multiple higher-coupon existing notes (including 2027–2031 sustainability-linked and other senior notes) and pay related fees and expenses, with any remainder for general corporate purposes including repayment of other outstanding debt.
Teva reports net revenues of $17.3 billion for the LTM ended June 30, 2026, GAAP operating income of $1.6 billion, net income attributable to Teva of $706 million, Non-GAAP operating income of $4.2 billion and Adjusted EBITDA of $4.6 billion. As of June 30, 2026, Teva had total assets of $39.9 billion, total liabilities of $32.1 billion, total equity of $7.8 billion and cash and cash equivalents of $3.7 billion. Capitalization data show the new notes and assumed $4.7 billion (equivalent) of redemptions primarily as a refinancing of existing debt rather than incremental leverage.
Teva Pharmaceutical Industries Ltd. (TEVA) announced that its Dutch financing subsidiaries priced a multi‑tranche offering of approximately $4.9 billion (equivalent) in senior notes, guaranteed on a senior unsecured basis by Teva. The new Securities comprise €1,000,000,000 of 4.250% notes due 2033, €500,000,000 of 4.625% notes due 2036, $1,000,000,000 of 5.500% notes due 2034, $1,000,000,000 of 5.750% notes due 2037, and $1,200,000,000 of 5.250% notes due 2032, each priced slightly below par. Settlement is expected on or about September 16, 2026, subject to customary closing conditions.
Teva expects to use the net proceeds, together with cash on hand, to fund conditional redemptions of several higher‑coupon outstanding series, including all 6.750% Senior Notes due 2028, all 7.875% and 7.375% Sustainability‑Linked Senior Notes due 2029, up to $450,000,000 of 4.750% Sustainability‑Linked Notes due 2027, and up to €1,150,000,000 of 4.375% Sustainability‑Linked Notes due 2030, as well as to pay related fees and, to the extent of any remaining proceeds, for general corporate purposes, including repayment of other debt.
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) is issuing new senior unsecured Euro- and U.S. dollar‑denominated notes through three Dutch finance subsidiaries, with all principal and interest unconditionally guaranteed by Teva. The notes have maturities in 2032, 2033, 2034, 2036 and 2037 and pay annual interest in euros and semi‑annual interest in U.S. dollars.
Teva expects to use the net proceeds, together with cash on hand, primarily to fund conditional redemptions of existing higher‑coupon debt, including all outstanding 6.750% Senior Notes due 2028, all 7.875% and 7.375% sustainability‑linked Senior Notes due 2029, up to $450 million of 4.750% sustainability‑linked Senior Notes due 2027 and up to €1.25 billion of 4.375% sustainability‑linked Senior Notes due 2030, plus related fees and expenses, with any remainder used for general corporate purposes and further debt repayment.
Teva reports 2025 net revenues of $17.26 billion, GAAP net income attributable to Teva of $1.41 billion and Adjusted EBITDA of $5.31 billion, with total assets of $40.75 billion and total equity of $7.91 billion as of December 31, 2025. As of June 30, 2026, cash and cash equivalents were $3.66 billion and total short‑term debt was $4.50 billion.
Teva Pharmaceutical Industries Limited (TEVA) reports a change in how it presents its operating segments and has retrospectively recast prior disclosures from its Form 10‑K for the year ended December 31, 2025. Effective January 1, 2026, Anda, Teva’s U.S. distribution business, is no longer part of the United States segment and is reported within Other Activities.
The recast updates segment information in Business, Management’s Discussion and Analysis, and Financial Statements and Supplementary Data to align with Teva’s Pivot to Growth strategy and internal reporting. Teva states that consolidated balance sheets, income statements, cash flows and other disclosures from the original 2025 Form 10‑K are unchanged, and no new events after that report are reflected.
Teva Pharmaceutical Industries Ltd. (TEVA) reported a material modification to the rights of its security holders by amending its deposit agreement and updating the form of American depositary receipt in connection with terminating its American depositary share (ADS) program. Each ADS represents one ordinary share, par value NIS 0.10 per share.
The amendment establishes a mandatory exchange under which each ADS will be exchanged for one ordinary share, and all outstanding ADSs will be cancelled in exchange for an equal number of economically equivalent ordinary shares listed on the New York Stock Exchange. The termination of the ADS program is expected to occur at the open of business (New York time) on September 14, 2026.